



HR0138

LRB102 17334 MST 22824 r

1

HOUSE RESOLUTION

2
3
4
5
6
7

WHEREAS, Precision medicine, which is also called personalized health care or individualized medicine, is an evolving field in which healthcare providers use analysis of a patient's biospecimen, known as biomarker testing, to determine which medical treatments will work best for each patient; and

8
9
10
11
12

WHEREAS, By combining the data from biomarker testing with an individual's medical history, circumstances, and values, healthcare providers can direct a patient to targeted treatment, which benefits both patients and the overall healthcare system; and

13
14
15

WHEREAS, The field of precision medicine holds great promise in ensuring the delivery of the right treatment to the right patient at the right time; and

16
17

WHEREAS, Sixty percent of treatments in preclinical development rely on biomarker data; and

18
19
20

WHEREAS, Biomedicine and the understanding of the characteristics of a patient's disease that informs precision medicine is evolving rapidly; and

1 WHEREAS, Healthcare providers are increasingly gaining
2 access to new technologies, such as biomarker testing, that
3 can help identify gene mutations, alterations, or protein
4 expressions specific to individual patients; and

5 WHEREAS, Health outcomes are improved through the use of
6 precision medicine; for example, patients with certain types
7 of lung cancer who received biomarker testing had a 28 percent
8 reduction in mortality; and

9 WHEREAS, The National Academy of Medicine considers
10 biomarker tests to be "key to unlocking the promise" of
11 personalized health care; and

12 WHEREAS, Biomarker testing is available for an
13 ever-increasing range of conditions and diseases, but patient
14 access to these tests is not keeping pace with the rate of
15 innovation; and

16 WHEREAS, A lack of awareness among providers and patients,
17 a lack of common terminology, and deficient coverage policies
18 by both public and private payers are preventing effective
19 adoption and integration of biomarker testing into precision
20 medicine and appropriate awareness and education about the
21 ways biomarker testing can be used to support diagnosis,
22 treatment, and monitoring of patients in a personalized way;

1 and

2 WHEREAS, The Illinois Department of Public Health and
3 other relevant partners seek to promote awareness, education,
4 and action related to improving access to biomarker testing;
5 therefore, be it

6 RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE
7 HUNDRED SECOND GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that
8 we declare March 2021 as "Precision Medicine and Biomarker
9 Testing Awareness Month" to raise awareness, encourage
10 education, and improve understanding of the ways biomarker
11 testing can be used to support diagnosis, treatment, and
12 monitoring of patients in a personalized way and the
13 importance of ensuring access to these promising technologies.